Additionally, pretreatment with rapamycin led to a significant reduction of ghrelin-induced proliferation in colon and breast cancer cells [46,55], and LY294002 and PD98059 (an inhibitor of MAPK), have independently demonstrated a role in partially blocking ghrelin-induced proliferation [56]. Here, GHRL is linked to breast cancer.